denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Treatment Considerations, Technology and Procedures
Description:
On the spectrum of plasma cell dyscrasias monoclonal gammopathy of undetermined significance (MGUS) represents the most commonly encountered condition in clinical practice. While it is clinically silent, the premalignant MGUS clone has the potential to progress to multiple myeloma or a related B-cell lymphoproliferative malignancy usually associated with high tumor burden. In contrast, monoclonal gammopathy of clinical significance (MGCS) is characterized by a small quiescent B-cell clone but significant symptoms caused by the monoclonal immunoglobulin affecting the skin, kidneys and/or nervous system.
Dr. Michaela Liedtke will present recent updates in the epidemiology of MGUS and prevalence of associated conditions based on population screening studies. Recommendations for a cost-effective diagnostic and follow-up approach will be discussed as well as diagnostic advances including mass spectrometry and revised light chain criteria. We will review updates in MGUS risk stratification related to genetics and other clone & host factors and discuss evidence for the emerging role of lifestyle interventions. The presentation will conclude with a brief overview of MGCS and highlight the clinical features and international collaboration that led to the discovery of TEMPI syndrome.
Dr Frank Bridoux will present the main characteristics of the different types of renal disorders associated with MGUS and introduce the concept of monoclonal gammopathy of renal significance (MGRS). The classification of MGRS-related renal disorders will be presented as well as the diagnostic work-up. The principles of hematologic and renal management of MGRS will be described.
Dr. Maite Cibeira will talk to us about monoclonal gammopathy of neurological significance with the aim of simplifying the hematologist’s diagnostic approach, in close collaboration with the neurologist. She will also discuss the available treatment strategies taking into account the rarity of these diseases, which makes it difficult to conduct clinical trials and explains the lack of standardized treatment options, as well as the relevance of supportive care in the context of an essential multidisciplinary management.
Dr. Michaela Liedtke will present recent updates in the epidemiology of MGUS and prevalence of associated conditions based on population screening studies. Recommendations for a cost-effective diagnostic and follow-up approach will be discussed as well as diagnostic advances including mass spectrometry and revised light chain criteria. We will review updates in MGUS risk stratification related to genetics and other clone & host factors and discuss evidence for the emerging role of lifestyle interventions. The presentation will conclude with a brief overview of MGCS and highlight the clinical features and international collaboration that led to the discovery of TEMPI syndrome.
Dr Frank Bridoux will present the main characteristics of the different types of renal disorders associated with MGUS and introduce the concept of monoclonal gammopathy of renal significance (MGRS). The classification of MGRS-related renal disorders will be presented as well as the diagnostic work-up. The principles of hematologic and renal management of MGRS will be described.
Dr. Maite Cibeira will talk to us about monoclonal gammopathy of neurological significance with the aim of simplifying the hematologist’s diagnostic approach, in close collaboration with the neurologist. She will also discuss the available treatment strategies taking into account the rarity of these diseases, which makes it difficult to conduct clinical trials and explains the lack of standardized treatment options, as well as the relevance of supportive care in the context of an essential multidisciplinary management.